Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.99%. The profit margin, also known as the revenue ratio or gross profit ratio ...
Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LCTX stock, giving a Buy rating on January 3.Stay Ahead of the ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
National American University Holdings Inc (NAUH) is expected to report for 2Q. Neogen Corp (NEOG) is expected to report $-0.01 for 2Q. NexImmune Inc (NEXI) is expected to report for 3Q.
Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.